A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial

Cannata-Andía, Jorge B.; Díaz-Sottolano, Augusto; Fernández, Pehuén; Palomo-Antequera, Carmen; Herrero-Puente, Pablo; Mouzo, Ricardo; Carrillo-López, Natalia; Panizo, Sara; Ibañez, Guillermo H.; Cusumano, Carlos A.; Ballarino, Carolina; Sánchez-Polo, Vicente; Pefaur-Penna, Jacqueline; Maderuelo-Riesco, Irene; Calviño-Varela, Jesús; Gómez, Mónica D.; Gómez-Alonso, Carlos; Cunningham, John; Naves-Díaz, Manuel; Douthat, Walter; Fernández-Martín, José L.

doi:10.1186/s12916-022-02290-8

Table 5 Multivariate analysis of the association between serum calcidiol at admission and pulmonary involvement, length of hospitalization, admission to ICU and mortality

From: A single-oral bolus of 100,000 IU of cholecalciferol at hospital admission did not improve outcomes in the COVID-19 disease: the COVID-VIT-D—a randomised multicentre international clinical trial

Pulmonary involvement at hospital admission^a (binary logistic regression)
Serum calcidiol >25 vs. ≤10 ng/mL	n	Odds ratio[95%CI]	p-value
Unadjusted	538	0.18[0.08–0.45]	<0.001
Adjusted by demographics	538	0.21[0.08–0.53]	0.001
Adjusted by demographics and comorbidities	538	0.20[0.08–0.51]	0.001
Adjusted by demographics, comorbidities and laboratory parameters	476	0.21[0.08–0.60]	0.003
Age-matched	325	0.25[0.08–0.74]	0.012
Patients not treated with cholecalciferol	235	0.14[0.03–0.59]	0.007
Days of hospitalization (Linear regression)
Serum calcidiol >25 vs. ≤10 ng/mL	n	Coefficient[95%CI]	p-value
Unadjusted	502	−4.08[−6.81–−1.36]	0.003
Adjusted by demographics	502	−3.69[−6.42–−0.96]	0.008
Adjusted by demographics and comorbidities	502	−3.64[−6.37–−0.90]	0.009
Adjusted by demographics, comorbidities and laboratory parameters	444	−3.69[−6.47–−0.90]	0.010
Age-matched	303	−4.41[−7.57–−1.25]	0.007
Patients not treated with cholecalciferol	222	−4.41[−8.09–−0.73]	0.020
Admission to ICU (Cox regression)
Serum calcidiol >25 vs. ≤10 ng/mL	n	Hazard ratio[95%CI]	p-value
Unadjusted	533	0.30[0.12−0.73]	0.008
Adjusted by demographics	533	0.33[0.13−0.82]	0.017
Adjusted by demographics and comorbidities	533	0.34[0.13−0.84]	0.019
Adjusted by demographics, comorbidities and laboratory parameters	471	0.35[0.13−0.95]	0.039
Age-matched	322	0.30[0.11−0.83]	0.021
Patients not treated with cholecalciferol	232	0.32[0.08−1.25]	0.101
Mortality (Cox regression)
Serum calcidiol >25 vs. ≤10 ng/mL	n	Hazard ratio[95%CI]	p-value
Unadjusted	538	1.10[0.39−3.08]	0.853
Adjusted by demographics	538	1.13[0.40−3.18]	0.810
Adjusted by demographics and comorbidities	538	1.32[0.44−3.91]	0.618
Adjusted by demographics, comorbidities and laboratory parameters	476	2.17[0.66−7.17]	0.205
Age-matched	325	1.90[0.51−7.11]	0.341
Patients not treated with cholecalciferol	235	4.99[0.74−33.45]	0.098

^aAssessed by X-ray and/or computed axial tomography
Demographic variables: age and sex
Comorbidity variables: diabetes, cardiovascular disease, hypertension, asthma and chronic obstructive pulmonary disease
Laboratory parameters: C-reactive protein and leucocytes
Age-matched: age-matched patients by calcidiol categories. Adjusted by sex, comorbidities and laboratory parameters
Patients not treated with cholecalciferol: adjusted by demographics, comorbidities and laboratory parameters

Back to article page

ISSN: 1741-7015

Contact us

Submission enquiries: bmcmedicineeditorial@biomedcentral.com
General enquiries: info@biomedcentral.com

BMC Medicine

Contact us